1. Home
  2. NEPH vs SABS Comparison

NEPH vs SABS Comparison

Compare NEPH & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEPH
  • SABS
  • Stock Information
  • Founded
  • NEPH 1997
  • SABS 2014
  • Country
  • NEPH United States
  • SABS United States
  • Employees
  • NEPH N/A
  • SABS N/A
  • Industry
  • NEPH Medical/Dental Instruments
  • SABS Biotechnology: Pharmaceutical Preparations
  • Sector
  • NEPH Health Care
  • SABS Health Care
  • Exchange
  • NEPH Nasdaq
  • SABS Nasdaq
  • Market Cap
  • NEPH 16.8M
  • SABS 15.8M
  • IPO Year
  • NEPH 2004
  • SABS N/A
  • Fundamental
  • Price
  • NEPH $2.16
  • SABS $1.85
  • Analyst Decision
  • NEPH Buy
  • SABS Strong Buy
  • Analyst Count
  • NEPH 1
  • SABS 6
  • Target Price
  • NEPH $5.00
  • SABS $11.17
  • AVG Volume (30 Days)
  • NEPH 7.2K
  • SABS 58.6K
  • Earning Date
  • NEPH 05-08-2025
  • SABS 05-27-2025
  • Dividend Yield
  • NEPH N/A
  • SABS N/A
  • EPS Growth
  • NEPH N/A
  • SABS N/A
  • EPS
  • NEPH 0.08
  • SABS N/A
  • Revenue
  • NEPH $15,517,000.00
  • SABS $377,835.00
  • Revenue This Year
  • NEPH $9.23
  • SABS N/A
  • Revenue Next Year
  • NEPH $12.99
  • SABS $50.00
  • P/E Ratio
  • NEPH $29.50
  • SABS N/A
  • Revenue Growth
  • NEPH 10.34
  • SABS N/A
  • 52 Week Low
  • NEPH $1.36
  • SABS $1.00
  • 52 Week High
  • NEPH $2.55
  • SABS $5.01
  • Technical
  • Relative Strength Index (RSI)
  • NEPH 60.72
  • SABS 58.32
  • Support Level
  • NEPH $2.06
  • SABS $1.76
  • Resistance Level
  • NEPH $2.23
  • SABS $2.15
  • Average True Range (ATR)
  • NEPH 0.16
  • SABS 0.19
  • MACD
  • NEPH 0.02
  • SABS 0.02
  • Stochastic Oscillator
  • NEPH 80.00
  • SABS 51.61

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: